Eli Lilly and Company flies to New York after blockbuster earnings raise

Eli Lilly and Company dispatched its Gulfstream G500, tail number N308EL, from Indianapolis International Airport to Teterboro Airport on May 10, 2026. The 92-minute flight, reaching 45,000 feet and topping 584 knots, touched down late evening in the New York area—a hub for high-stakes business dealings.

The timing aligns with the afterglow of Eli Lilly and Company's first-quarter results, announced April 30, which showed revenue jumping 56% to $19.8 billion, propelled by GLP-1 drugs like Mounjaro and Zepbound, per the company's press release. Management raised full-year 2026 revenue guidance to $82-85 billion and non-GAAP EPS to $35.50-37.00, signaling robust demand for obesity treatments. Such trips often follow earnings to court analysts and partners on Wall Street.

This jaunt fits Eli Lilly and Company's recurring New York visits, alongside destinations like London and Frankfurt for global pharma business. Recent flights shuttled executives to Seattle and San Francisco, likely chasing tech collaborations, before returning home—patterns underscoring the CEO's peripatetic push amid the firm's momentum in weight-loss innovation.